Calidi Biotherapeutics (CLDI) Operating Expenses (2022 - 2025)

Calidi Biotherapeutics has reported Operating Expenses for 4 years, with the latest figure at $4.5 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 10.93% year-over-year to $4.5 million; the trailing twelve-month figure through Dec 2025 stood at $20.2 million (down 7.05% YoY), and the FY2025 full-year result was $20.2 million, down 7.05% from the prior year.
• Operating Expenses for Q4 2025 stood at $4.5 million, down from $5.0 million in the prior quarter.
• The five-year high for Operating Expenses was $9.8 million in Q4 2023, with the low at $361622.0 in Q2 2022.
• Average Operating Expenses over 4 years is $5.2 million, with a median of $5.3 million recorded in 2023.
• Year-over-year, Operating Expenses jumped 1707.69% in 2023 and plunged 59.0% in 2024.
• Tracing CLDI's Operating Expenses over 4 years: stood at $4.7 million in 2022, then jumped by 109.47% to $9.8 million in 2023, then sank by 59.0% to $4.0 million in 2024, then advanced by 10.93% to $4.5 million in 2025.
• The last three Operating Expenses figures came in at $4.5 million (Q4 2025), $5.0 million (Q3 2025), and $5.7 million (Q2 2025), per Business Quant data.

Peer Comparison